STAT3 and hereditary clear cell renal cell carcinoma: STAT3 is considered to be a promising therapeutic target for a variety of kidney diseases, including diabetic nephropathy, acute kidney injury, lupus nephritis, polycystic kidney disease, and renal cell carcinoma (Bienaimé et al., 2016; Yu et al., 2023).